摘要 |
Novel imidazoquinoxalines of the formula <IMAGE> I wherein R1 is selected from the group consisting of hydroxy, alkoxy of 1 to 5 carbon atoms and cyclohexylcarbonyloxymethoxy, R2 is selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms, alkoxycarbonylvinyl of 4 to 7 carbon atoms, -COR, -CONH(CH2)n-X and -A-(CH2)m-Y, R is selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, alkenyl of 2 to 4 carbon atoms, alkoxy of 1 to 5 carbon atoms, alkoxycarbonyl of 2 to 5 carbon atoms, amino, -CF3, -CHCl2-, phenyl, aralkyl of 7 to 10 carbon atoms, aralkoxy of 7 to 10 carbon atoms, n is 0 and X is phenyl or n is an integer from 1 to 5 and X is selected from the group consisting of <IMAGE> +TR <IMAGE> R3 and R4 are individually selected from the group consisting of hydrogen, alkyl of 1 to 5 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, aryl of 6 carbon atoms and aralkyl of 7 to 8 carbon atoms or R3 and R4 taken together with the nitrogen atom to which they are attached form a saturated heterocycle with 4 to 8 ring carbon atoms optionally containing at least one oxygen atom or sulfur atom or nitrogen atom optionally substituted with alkyl of 1 to 3 carbon atoms or alkoxycarbonyl of 2 to 5 carbon atoms, Hal is chlorine or bromine, A is selected from the group consisting of <IMAGE> m is a integer from 1 to 3, Y is <IMAGE> their non-toxic, pharmaceutically acceptable acid addition salts when R1 is other than -OH and their salts with pharmaceutically acceptable metals or nitrogen bases when R1 is -OH, having antiallergic properties. |